AN2 Therapeutics Reports Phase 3 Portion Of Previously Terminated EBO-301 Study Data; Outlines Future Milestones From Boron Chemistry Pipeline
Benzinga Newsdesk 1 year ago
BiotechNewsGeneral
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung diseaseExtensive enabling NTM data
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease
Extensive enabling NTM data provides potential path forward in M. abscessus lung disease
Company focus remains centered on boron chemistry pipeline with initiation of high impact clinical programs in infectious diseases and an emerging oncology portfolio
Initiated start up activities for Phase 1 first in human study in healthy volunteers of AN2-502998, under development to treat chronic Chagas disease
Topline data for standard-of-care melioidosis observational trial expected in 2Q25; Phase 2 study planned for 2H25 with goal of reducing mortality from observed rates approaching 40%
First oncology compound(s) from boron chemistry platform on track to advance into development in 2H25; targets best-in-class profiles with fully owned IP; novel oncology compounds target ENPP1, PI3Kα and other undisclosed targets for solid tumor indications
Company extends cash runway into 2028, implements strategic measures to optimize operations and enhance shareholder value